Development and validation of a next-generation sequencing-based multigene assay to predict the prognosis of estrogen receptor-positive, HER2-negative breast cancer.

CONCLUSIONS: The newly developed and validated NGS-based multigene assay can predict the distant recurrence risk in ER-positive, HER2-negative breast cancer.
PMID: 33028590 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - October 7, 2020 Category: Cancer & Oncology Authors: Lee HB, Lee SB, Kim M, Kwon S, Jo J, Kim J, Lee HJ, Ryu HS, Won Lee J, Kim C, Jeong J, Kim H, Noh DY, Park IA, Ahn SH, Kim S, Yoon S, Kim A, Han W Tags: Clin Cancer Res Source Type: research